<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Frontotemporal dementia: Clinical features and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Frontotemporal dementia: Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Frontotemporal dementia: Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Suzee E Lee, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H533509364"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Frontotemporal dementias (FTDs) are a group of clinically and neuropathologically heterogeneous neurodegenerative disorders characterized by prominent changes in social behavior and personality or aphasia accompanied by degeneration of the frontal and/or temporal lobes. Some patients with FTD also develop a concomitant motor syndrome such as parkinsonism or motor neuron disease (MND). FTD is one of the more common causes of early-onset dementia, with an average age of symptom onset in the sixth decade.</p><p>This topic will review the clinical features and diagnosis of the main clinical syndromes of FTD. The treatment of FTD and the genetics, pathology, and pathogenesis of FTD are discussed separately. (See  <a class="medical medical_review" href="/d/html/14139.html" rel="external">"Frontotemporal dementia: Treatment"</a> and  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H533509392"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Terminology for FTD has evolved over time. In 1892, Arnold Pick first described a patient with progressive aphasia and focal frontotemporal atrophy [<a href="#rid1">1</a>]. Alois Alzheimer later characterized the disorder as "Pick disease," defined by distinctive round, silver-staining inclusions called Pick bodies [<a href="#rid2">2</a>]. Subsequent clinicopathologic studies determined that many patients diagnosed clinically with Pick disease did not have Pick neuropathology at autopsy, and thus Pick disease now designates the pathologic diagnosis, rather than a clinical syndrome.</p><p>The term "FTD" serves as an umbrella term for three clinical presentations: behavioral variant FTD (bvFTD) and two forms of primary progressive aphasia (PPA), the nonfluent and semantic variants. Historically, bvFTD has also been called "FTD" or "frontal variant FTD," while semantic variant PPA has been called "temporal variant FTD" and "semantic dementia." Nonfluent variant PPA is also referred to as "agrammatic PPA." The third variant of PPA, the logopenic variant, is typically associated with Alzheimer pathology and is not included as one of the three clinical FTD syndromes.</p><p>The pathology underlying clinically defined FTD is heterogeneous. The term "frontotemporal lobar degeneration" (FTLD) refers to this group of neuropathologic diagnoses, further categorized by abnormal protein inclusions due to tau, TDP-43, and other proteins. Distinguishing between clinical and neuropathologic disease definitions is important, since clinicopathologic series have revealed that clinical syndromes often fail to predict underlying pathology. The pathologic features of FTD are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H533509426"><span class="h1">BEHAVIORAL VARIANT FTD</span><span class="headingEndMark"> — </span>Behavioral variant FTD (bvFTD) is the most common clinical subtype, comprising approximately half of all cases of FTD. The hallmark of bvFTD is progressive changes in personality and behavior early in the disease course [<a href="#rid3">3</a>]. These behavioral symptoms represent a significant and persistent shift from the premorbid personality.</p><p>Disease onset usually occurs during the sixth decade but has been reported as early as the second decade and as late as the ninth. Because of their overlap with psychiatric disorders, symptoms in bvFTD often precede the correct diagnosis by several years [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'Epidemiology'</a>.) </p><p class="headingAnchor" id="H533509472"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Early behavioral changes of bvFTD include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Disinhibition – Examples of disinhibition or socially inappropriate behavior include touching or kissing strangers, public urination, and flatulence without concern. Patients may make offensive remarks or invade others' personal space. Patients with FTD may exhibit utilization behaviors, such as playing with objects in their surroundings or taking others' personal items.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apathy and loss of empathy – Apathy manifests as losing interest and/or motivation for activities and social relationships. Patients may participate less in conversations and grow passive. Apathy is mistaken frequently for depression, and patients are often referred for psychiatric treatment early in the disease course.</p><p></p><p class="bulletIndent1">As patients lose empathy, caregivers may describe patients as cold or unfeeling towards others' emotions. Degeneration of right orbitofrontal and anterior temporal regions is associated with the loss of sympathy and empathy [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperorality – Hyperorality and dietary changes manifest as altered food preferences, such as carbohydrate cravings, particularly for sweet foods, and binge eating. Increased consumption of alcohol or tobacco may occur. Patients may eat beyond satiety or put excessive amounts of food in their mouths that cannot be chewed properly. They may attempt to consume inedible objects. This behavior correlates with right orbitofrontal, insular, striatal and hypothalamic degeneration [<a href="#rid7">7-9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compulsive behaviors – Perseverative, stereotyped, or compulsive ritualistic behaviors include stereotyped speech, simple repetitive movements, and complex ritualistic behaviors such as hoarding, checking, or cleaning. Some patients develop new hobbies or interests, particularly those with a religious aspect, which are pursued obsessively. Other behaviors traditionally associated with obsessive compulsive disorder, such as handwashing and germ phobias, are generally absent. Patients with FTD can develop a rigid personality, rigid food preferences, and inflexibility to changes in routine. </p><p></p><p>Most patients lack insight into their behavioral changes and the distress experienced by their family members [<a href="#rid10">10</a>]. To probe for a history of subtle behavioral changes, it may be useful to ask caregivers about the following [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Has the patient said or done anything in public that has embarrassed others?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient appear to have a lack of disgust?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient seem indifferent or oblivious to others' feelings and less warm or affectionate, especially toward grandchildren or pets?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Have food preferences changed or table manners declined?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient seem more concerned with timekeeping or tend to watch the clock?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Has there been a change in the patient's sense of humor?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Has the patient developed new hobbies or interests pursued obsessively, especially with a religious or spiritual bent?</p><p></p><p>Patients with bvFTD generally lack cranial nerve, sensory, cerebellar, pyramidal, and extrapyramidal motor findings, at least initially. Frontal release signs may be seen, but the diagnostic utility of these signs is low, as they are not specific to FTD. In later stages of bvFTD, disinhibition and compulsive behaviors often wane as patients grow more apathetic, reflecting further degeneration in the medial frontal cortex [<a href="#rid5">5</a>]. Parkinsonism may also emerge in advanced stages of the disease.</p><p>Approximately 15 to 20 percent of patients with bvFTD develop concomitant motor neuron disease (MND); less frequently they may exhibit clinical features of either corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP). (See <a class="local">'Motor syndromes associated with FTD'</a> below.)</p><p class="headingAnchor" id="H533509621"><span class="h2">Neuropsychologic testing</span><span class="headingEndMark"> — </span>Patients with bvFTD typically score well on neuropsychologic testing early in the course of the disease. Neuropsychologic measures of executive function largely test frontal lobe functions referable to the dorsolateral prefrontal cortex, a region that is spared in early stages of bvFTD.</p><p>In early bvFTD, damage to medial frontal and orbitofrontal regions is associated with apathy and disinhibition. Measures of social cognition include impairments in recognizing affect, emotions, and sarcasm [<a href="#rid12">12</a>] and difficulty understanding another person's perspective [<a href="#rid13">13</a>].</p><p>As the disease involves dorsolateral prefrontal regions, executive functions such as set-shifting and verbal fluency decline. Memory and visuospatial functions are usually spared in bvFTD, although frontal lobe dysfunction can make it appear to families that patients have memory problems. Memory impairment, when present, has been associated with an increased rate of progression in several studies [<a href="#rid14">14,15</a>]. Apathy and poor attention and planning make it challenging to interpret neuropsychologic test results in many patients with bvFTD.</p><p class="headingAnchor" id="H533509669"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Structural and functional imaging provides supportive but not diagnostic evidence for bvFTD [<a href="#rid16">16-18</a>], as neuroimaging may appear normal upon visual inspection early in the disease course [<a href="#rid19">19,20</a>]. As the disease progresses, focal frontal or temporal atrophy manifests in 50 to 65 percent of patients [<a href="#rid21">21-23</a>] and targets the anterior insula, anterior cingulate cortex, and amygdala [<a href="#rid24">24-27</a>]. Atrophy may affect one brain hemisphere more than the other; over time, homologous regions in the other hemisphere degenerate.</p><p>The earliest regions of damage in bvFTD are usually (but not always) right hemispheric and include the anterior insula, pregenual anterior cingulate, and orbitofrontal cortex. Neuroanatomic-behavior correlation studies reveal that medial frontal and anterior cingulate damage correlates with apathy, while right anterior temporal and right medial frontal atrophy correlates with loss of empathy [<a href="#rid6">6,28</a>]. Damage to orbitofrontal, right insula and striatum correlates with changes in eating behavior [<a href="#rid7">7-9</a>]. Simple motor stereotypies correlate with striatal atrophy, while complex ritualistic compulsions are related to atrophy in orbitofrontal, caudate, and temporal lobe atrophy [<a href="#rid29">29,30</a>]. In patients with bvFTD and MND, magnetic resonance imaging (MRI) may demonstrate atrophy in premotor regions and precentral gyri [<a href="#rid31">31</a>]. </p><p>The magnitude of frontotemporal atrophy not only varies with respect to disease duration but may also vary with respect to the age of symptom onset. In an autopsy series of over 100 cases of pathology-confirmed frontotemporal lobar degeneration (FTLD), the majority of cases with an age of onset &lt;65 years had evidence of moderate to severe frontotemporal atrophy and ventricular dilation at autopsy, while only 40 percent of the late-onset cases had severe frontotemporal atrophy [<a href="#rid32">32</a>].</p><p>Functional neuroimaging studies (single-photon emission computed tomography [SPECT], perfusion MRI, or positron emission tomography [PET]) demonstrating frontal or frontotemporal hypoperfusion or hypometabolism may be more sensitive than MRI in the early stages of disease, but are not in themselves diagnostic [<a href="#rid16">16,17,33</a>]. Diffusion tensor imaging shows abnormal diffusivity in gray matter in these regions [<a href="#rid34">34</a>]. In contrast with amyloid PET tracers, which show promise for distinguishing Alzheimer disease (AD) dementia from non-Alzheimer neurodegenerative disorders, tau PET tracers appear to have less specificity [<a href="#rid35">35,36</a>], but new tau PET tracers are currently being researched for specificity and sensitivity to FTLD-tau pathologies.</p><p class="headingAnchor" id="H533510009"><span class="h2">Diagnosis</span></p><p class="headingAnchor" id="H267435090"><span class="h3">Evaluation</span><span class="headingEndMark"> — </span>The diagnosis of bvFTD is made primarily by clinical assessment. Patients are generally not reliable informants of behavioral problems (because of their lack of insight), and interviewing family members is crucial [<a href="#rid37">37</a>]. The presence of abnormal social conduct, eating disorders, stereotyped behaviors, and akinesia/apathy along with the absence of significant memory or visual spatial deficits are very specific (close to 99 percent) and moderately sensitive (80 to 85 percent) for the diagnosis of bvFTD [<a href="#rid21">21,24,38-44</a>].</p><p>Computed tomography (CT) or MRI brain scans are required to exclude structural pathology; atrophy patterns found on such scans may support the diagnosis. Neuropsychologic testing may be helpful in distinguishing bvFTD from other neurodegenerative syndromes and psychiatric disorders, but similar to structural brain imaging, findings on neuropsychologic testing are supportive rather than diagnostic. Other laboratory tests are typically performed to exclude potentially reversible contributors or causes of cognitive impairment. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia"</a>.)</p><p>Clinicopathologic studies suggest that bvFTD can be diagnosed fairly reliably in life, although occasionally Alzheimer pathology manifests as bvFTD [<a href="#rid45">45</a>]. </p><p class="headingAnchor" id="H3038376373"><span class="h3">Diagnostic criteria for bvFTD</span><span class="headingEndMark"> — </span>In 2011, the International Behavioral Variant FTD Criteria Consortium (FTDC) published new criteria for bvFTD, building upon the 1998 Neary criteria [<a href="#rid16">16</a>]. The FTDC criteria synthesize clinical features, neuroimaging, neuropathology, and genetic testing [<a href="#rid16">16,17</a>]. A diagnosis of possible bvFTD is based solely on the clinical syndrome and aims to identify patients at the mildest stages of disease.</p><p>Possible bvFTD requires a combination of three of six clinical features:</p><p class="bulletIndent1"><span class="glyph">●</span>Disinhibition</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apathy/inertia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss of sympathy/empathy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perseverative/compulsive behaviors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperorality</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysexecutive neuropsychologic profile</p><p></p><p>Probable FTD requires the same clinical criteria, plus demonstrable functional decline and imaging findings that reflect the principal anatomic location of neurodegeneration in bvFTD (ie, frontal and/or temporal lobe atrophy, hypometabolism, or hypoperfusion).</p><p>Both possible and probable bvFTD require the exclusion of other neurologic, medical, and psychiatric disorders that would better account for the pattern of deficits and behavioral disturbance.</p><p>A third diagnostic category, bvFTD with definite FTLD pathology, is satisfied when cases of possible or probable bvFTD are accompanied by either biopsy or postmortem histopathologic evidence of FTLD or evidence of a known pathogenic mutation. (See  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'Genetic factors'</a>.)</p><p>Using pathologically confirmed cases of FTLD as a gold standard, the FTDC criteria for possible and probable bvFTD have a sensitivity of 85 and 75 percent, respectively [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H533510349"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>Once systemic medical illness, substance abuse, and non-neurodegenerative neurologic illnesses have been excluded, the main entities considered in the differential diagnosis for bvFTD are psychiatric disorders and other neurodegenerative disorders such as dementia with Lewy bodies and AD. In general, neuroimaging will reliably exclude non-neurodegenerative neurologic diseases affecting the frontal lobes, such as infarction, tumors, abscess, and trauma. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychiatric disorders </strong>– Depression, obsessive compulsive disorder, and bipolar disorder are often considered in an individual presenting with behavioral or personality changes; in particular, apathy associated with bvFTD is mistaken commonly for depression.</p><p></p><p class="bulletIndent1">Clues that such changes are early signs of bvFTD rather than depression may include lack of any prior psychiatric history and the emergence of certain specific behaviors such as changes in eating (as opposed to simply decreased appetite) or social faux pas. Occasionally, patients with bvFTD can appear euphoric [<a href="#rid11">11</a>]. While the usual age of onset of bvFTD is somewhat older than is typical for a first presentation of major psychiatric disease, there is substantial overlap. Changes are insidious in some, and therefore longitudinal clinical follow-up helps to establish the diagnosis of bvFTD versus psychiatric disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dementia with Lewy bodies</strong> – In the setting of neurodegenerative disease, delusions and hallucinations are more suggestive of dementia with Lewy bodies [<a href="#rid46">46</a>]. Psychosis, including hallucinations and delusions, is atypical for FTD [<a href="#rid46">46</a>], although psychosis may occur in 20 to 50 percent of bvFTD patients who carry the <em>C9orf72</em> hexanucleotide expansion, the most common genetic cause of sporadic and familial FTD and amyotrophic lateral sclerosis (ALS) [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'C9orf72 expansion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alzheimer disease</strong> – Patients with early-onset AD are frequently misdiagnosed with bvFTD and vice versa. Usually, patients with AD perform more poorly on measures of cognitive function referable to the medial temporal lobes (ie, episodic memory) and parietal lobes (ie, visuospatial skills and apraxia) than those with bvFTD. Patients with AD often perform poorly on measures of executive function and do not exhibit prominent loss of social cognition as an early feature of disease.</p><p></p><p class="bulletIndent1">Structural imaging can help elucidate focal atrophy patterns that differ between bvFTD (frontal and temporal cortices) and AD (medial temporal and parietal cortices) [<a href="#rid49">49</a>]. Biomarkers that strongly suggest AD include low beta amyloid and high phospho-tau in the cerebrospinal fluid. (See  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Role of biomarkers'</a>.)</p><p></p><p class="bulletIndent1">In addition to cerebrospinal fluid AD biomarkers, amyloid-binding PET ligands (florbetapir, flutemetamol, florbetaben) and tau-PET (flortaucipir) are useful for identifying AD pathology. PET scans do not yet have the capability to confirm FTLD pathology. Amyloid PET scans are not yet covered by most third-party payers, rendering them prohibitively expensive for most patients. Clinically, amyloid PET is most helpful in diagnosing early-onset AD. (See  <a class="medical medical_review" href="/d/html/98647.html" rel="external">"Early-onset dementia in adults"</a>.) </p><p></p><p class="headingAnchor" id="H533510559"><span class="h1">PRIMARY PROGRESSIVE APHASIA</span><span class="headingEndMark"> — </span>Primary progressive aphasia (PPA) is a clinical syndrome characterized by the insidious onset and gradual progression of a speech or language impairment manifested by deficits in speech apraxia, word finding, word usage, word comprehension, or sentence construction [<a href="#rid50">50,51</a>]. PPA arises when the language-dominant hemisphere is the principal target of neurodegeneration. PPA is characterized by isolated language deficits during early stages of the disease.</p><p>Three variants of PPA have been described based on the type of language impairment: nonfluent, semantic, and logopenic [<a href="#rid52">52</a>]. These patterns of language impairment in PPA reflect the anatomic distribution of peak atrophy sites. As neurodegeneration progresses in later stages of PPA, language remains the most affected cognitive domain, but other cognitive domains also decline. </p><p class="headingAnchor" id="H533510605"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The hallmark of PPA is early, progressive language disturbance leading to functional impairment with relative preservation of episodic memory and other cognitive domains. Language dysfunction is apparent during routine conversation and/or through speech and language assessments. Activities of daily living are maintained except those relating to language (eg, difficulty using the telephone) [<a href="#rid52">52</a>]. While other cognitive functions may be affected later in the course, language dysfunction remains the most impaired domain throughout the disease course. </p><p class="headingAnchor" id="H533510625"><span class="h3">Nonfluent variant PPA</span><span class="headingEndMark"> — </span>The core feature of nonfluent variant PPA is a motor speech deficit characterized by effortful production of the linguistic units of sound (phonemes). Although word finding is a common complaint across all PPA subtypes, the characteristic that distinguishes the nonfluent variant from other forms of PPA is articulatory difficulty. This is characterized by effortful, halting speech with inconsistent speech-sound errors and distortions and agrammatism in language production [<a href="#rid52">52</a>].</p><p>At the bedside, apraxia of speech can be tested by having the patient repeat a word such as "caterpillar" or "artillery" rapidly and repeatedly, since these words are particularly challenging to articulate. Sound distortions and difficulty pronouncing such words iteratively are characteristic of speech apraxia. These deficits correspond anatomically with atrophy within the left inferior frontal gyrus and posterior fronto-insula.</p><p>While comprehension is typically spared for single words and simple sentences, patients often have difficulty with complex sentences, particularly those with complex syntax, such as using the passive voice or multiple dependent clauses [<a href="#rid52">52</a>].</p><p>Social comportment, memory, visual spatial skills, and other cognitive abilities are typically preserved at the time of presentation [<a href="#rid53">53-56</a>]. While patients usually retain some insight, they may seem inappropriately unconcerned [<a href="#rid57">57</a>].</p><p>Deficits may be restricted to expressive language function for a few to several years before a more global dementia supervenes [<a href="#rid56">56,58</a>]. Some patients go on to develop behavioral alterations or symptoms of motor neuron disease (MND) or corticobasal syndrome (CBS) [<a href="#rid53">53,56,58-61</a>]. (See <a class="local">'Motor syndromes associated with FTD'</a> below.)</p><p class="headingAnchor" id="H533510887"><span class="h3">Semantic variant PPA</span><span class="headingEndMark"> — </span>The core features of semantic variant PPA are impaired single-word comprehension and object naming in the setting of preserved fluency, repetition, and grammar.</p><p>Word-finding difficulty, especially for low-frequency items, is the earliest symptom, and there is progressive loss of knowledge of the characteristics of objects. Early on, patients may exhibit a marked discrepancy between the ability to understand complete sentences, which tends to be preserved, and the ability to understand single object words, which is impaired [<a href="#rid51">51</a>]. As the disease progresses, language comprehension becomes more globally impaired.</p><p>Patients may also exhibit surface dyslexia or dysgraphia, in which words with irregular spellings (eg, yacht, colonel, tissue) are mispronounced or misspelled because the correct pronunciation or spelling relies on semantic knowledge.</p><p>At the bedside, the clinician can ask the patient to draw animals such as a turtle, dog, and bird; those with semantic variant PPA frequently make drawings of animals lacking defining features (eg, no shell for a turtle), demonstrating loss of semantic detail around a given animal. In patients with right greater than left temporal pole involvement, facial recognition of famous people may be impaired in the early stages of the disease [<a href="#rid62">62</a>]. </p><p>Although asymmetric atrophy of the temporal poles is typical in the early stages of semantic variant PPA, eventually the disease spreads to the contralateral side. With bilateral involvement, there is emergence of behavioral symptoms such as behavioral rigidity, parsimony of speech, loss of empathy, and hypergraphia. As disease spreads from anterior temporal lobes to mesial temporal cortices, episodic memory may decline, while visuospatial skills and executive function remain relatively intact [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H533510935"><span class="h3">Logopenic variant PPA</span><span class="headingEndMark"> — </span>The logopenic variant of PPA is typically associated with Alzheimer pathology and is not included as one of the three clinical FTD syndromes.</p><p>The logopenic variant of PPA features impaired single-word retrieval and repetition with errors in speech and naming, but with spared single-word comprehension and object knowledge, spared motor speech, and absence of agrammatism [<a href="#rid52">52</a>]. Like the nonfluent variant, speech can have a slow rate with frequent word-finding pauses and paraphasic errors. With logopenic variant PPA, however, slow rate is primarily due to word-finding pauses, rather than difficulties with word production, articulation, or apraxia of speech.</p><p>The speech of logopenic variant PPA has been described as "empty," in the sense that a patient might tell a story vaguely or with words that profoundly lack descriptive detail.</p><p>Phonological short-term memory deficits in logopenic variant PPA manifest as difficulty with long, grammatically complex sentences, although single-word repetition is spared. </p><p>The logopenic variant of PPA is typically associated with Alzheimer pathology and is not included as one of the three clinical FTD syndromes.</p><p class="headingAnchor" id="H533510955"><span class="h2">Neuropsychologic testing</span><span class="headingEndMark"> — </span>Neuropsychologic testing can help to discern a pattern of language deficits characteristic of one of the three clinical variants of PPA.</p><p>Patients with PPA typically perform well on tests of episodic memory, executive function, and visuospatial function in early stages of the disease [<a href="#rid64">64</a>]. Patients with nonfluent and logopenic PPA perform well on measures of social cognition, such as recognition of sarcasm, empathy, and the ability to understand others' perspectives. In semantic variant PPA, degeneration of right anterior temporal lobe often emerges, leading to decline in empathy and the emergence of coldness in personality profiles, increased rigidity, and interrupting others [<a href="#rid6">6</a>].</p><p>The language examination, including evaluation of articulation, grammar, fluency, and speech praxis, helps to differentiate among the nonfluent, semantic, and logopenic variants. In nonfluent variant PPA, testing reveals nonfluent speech, agrammatism, and apraxia of speech along with impaired naming and verbal fluency. In semantic variant PPA, testing reveals loss of word and object knowledge and surface dyslexia or dysgraphia. Speech errors and impairments in single-word retrieval and sentence repetition, with spared grammar, motor speech, and single-word comprehension, distinguish the logopenic variant from the nonfluent and semantic variants. A brief 30-point test has been developed for detecting PPA in speakers of French [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H533510989"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>As with behavioral variant FTD (bvFTD), structural and functional imaging in patients with PPA may demonstrate atrophy, hypometabolism, and/or hypoperfusion in the frontal and/or temporal lobes, in a pattern specific to the clinical variant.</p><p>In nonfluent variant PPA, atrophy emerges in left posterior fronto-insular cortex [<a href="#rid64">64</a>]. Functional imaging such as single-photon emission computed tomography (SPECT) or 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) may demonstrate predominant hypoperfusion or hypometabolism in left posterior fronto-insula [<a href="#rid52">52,59,64</a>]. Tau PET tracers are being studied in the evaluation of patients with neurodegenerative dementia. (See <a class="local">'Neuroimaging'</a> above.)</p><p>In semantic variant PPA, striking anterior temporal atrophy emerges, which is usually asymmetric [<a href="#rid64">64</a>]. Hypoperfusion or hypometabolism on SPECT or FDG-PET in anterior temporal lobes may also be present.</p><p>In logopenic variant PPA, structural imaging often shows predominant left posterior temporal cortex and parietal atrophy [<a href="#rid64">64</a>]. FDG-PET and SPECT may highlight hypometabolism or hypoperfusion in these brain regions. Amyloid PET imaging studies suggest that patients with logopenic variant PPA are likely to have Alzheimer pathology [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H533511093"><span class="h2">Diagnosis</span></p><p class="headingAnchor" id="H3461441209"><span class="h3">Evaluation</span><span class="headingEndMark"> — </span>PPA is a clinical diagnosis, made primarily by detailed history and neurologic examination in a patient presenting with progressive language dysfunction with sparing of other cognitive domains early in the disease course.</p><p>A structural neuroimaging study is required to exclude lesions that may cause progressive aphasia. While not diagnostic on their own, atrophy patterns are included as supportive criteria for PPA. For example, left posterior frontal atrophy is associated with nonfluent variant PPA, while left anterior temporal atrophy is characteristic in semantic variant PPA (and left parietal atrophy in logopenic variant PPA). Neuropsychologic testing can identify vulnerable linguistic features for speech therapy and also contributes to understanding possible neuropathologic diagnoses. As in other progressive cognitive syndromes, laboratory tests are typically performed to exclude potentially reversible contributors or causes of cognitive impairment. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H533511111"><span class="h3">Diagnostic criteria for PPA</span><span class="headingEndMark"> — </span>Clinical criteria for the diagnosis of PPA and its three clinical variants were established by international expert consensus in 2011  (<a class="graphic graphic_table graphicRef90758" href="/d/graphic/90758.html" rel="external">table 1</a>) [<a href="#rid52">52</a>]. These criteria incorporate clinical, imaging, and biomarker data and have replaced the older Neary criteria [<a href="#rid67">67</a>].</p><p>A diagnosis of PPA requires all of the following features [<a href="#rid52">52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The most prominent clinical feature is difficulty with language</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The language deficits are the principal cause of impaired activities of daily living</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aphasia is the most prominent deficit at symptom onset and for the initial phases of disease</p><p></p><p>In addition, the following four criteria must be answered negatively [<a href="#rid52">52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pattern of deficits is better accounted for by other non-neurodegenerative nervous system or medical disorders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive disturbance is better accounted for by a psychiatric diagnosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are prominent initial episodic memory, visual memory, and visuoperceptual impairments</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a prominent initial behavioral disturbance</p><p></p><p>Once a PPA diagnosis is established by these criteria, the aphasia is subclassified further as nonfluent variant  (<a class="graphic graphic_table graphicRef90759" href="/d/graphic/90759.html" rel="external">table 2</a>), semantic variant  (<a class="graphic graphic_table graphicRef90761" href="/d/graphic/90761.html" rel="external">table 3</a>), or logopenic variant  (<a class="graphic graphic_table graphicRef91662" href="/d/graphic/91662.html" rel="external">table 4</a>). This schema includes purely clinical diagnostic criteria as well as clinical diagnoses supported by neuroimaging findings such as atrophy (structural imaging), hypoperfusion (SPECT), hypometabolism (PET), or pathologic and genetic data.</p><p class="headingAnchor" id="H533511241"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>The majority of PPA cases are due to frontotemporal lobar degeneration (FTLD) or Alzheimer disease (AD) pathology.</p><p>Other considerations include cerebrovascular disease and a slowly growing mass lesion such as a brain tumor [<a href="#rid53">53,58,68-71</a>]. Thus, a neuroimaging study, usually brain computed tomography (CT) or magnetic resonance imaging (MRI), is important to exclude mass lesions and other structural pathology in patients with primary aphasia. (See  <a class="medical medical_review" href="/d/html/5106.html" rel="external">"Approach to the patient with aphasia"</a>.)</p><p class="headingAnchor" id="H533511373"><span class="h2">Clinicopathologic correlations</span><span class="headingEndMark"> — </span>At a group level, the three clinical variants of PPA correspond to different underlying neuropathologies, although prediction of an individual patient's underlying pathologic diagnosis remains challenging. Being able to determine the underlying pathologic diagnosis is important for enrollment in drug trials that are testing disease-modifying treatments and will become critical once such treatments may be available in the future.</p><p class="bulletIndent1"><span class="glyph">●</span>Most cases of nonfluent variant PPA are associated with tau-positive FTLD (FTLD-tau) [<a href="#rid53">53</a>], with 88 percent of patients showing FTLD-tau in one series [<a href="#rid72">72</a>], but FTLD with TDP43-positive inclusions (FTLD-TDP) type A pathology has also been reported [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Semantic variant PPA is most often linked to FTLD-TDP type C [<a href="#rid45">45</a>], with 83 percent of patients with this underlying pathology in one series [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most cases of logopenic variant PPA are due to underlying Alzheimer pathology, although hemispheric asymmetry in the distribution of neurofibrillary tangles distinguishes logopenic variant PPA from typical AD [<a href="#rid72">72-74</a>].</p><p></p><p>The heterogeneous pathologies underlying PPA suggest that the PPA clinical syndrome is determined not by the histopathology of the neurodegeneration but rather by its anatomic predilection for the language network of the brain [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis"</a>.) </p><p class="headingAnchor" id="H533511510"><span class="h1">MOTOR SYNDROMES ASSOCIATED WITH FTD</span><span class="headingEndMark"> — </span>Most patients with FTD (behavioral variant [bvFTD] or the primary progressive aphasias [PPAs]) do not manifest prominent motor features early in the disease course. However, there are three clinical syndromes that manifest with motor symptoms in addition to cognitive and behavioral symptoms, which may be caused by frontotemporal lobar degeneration (FTLD) pathology. </p><p class="headingAnchor" id="H533511546"><span class="h2">Behavioral variant FTD with motor neuron disease</span><span class="headingEndMark"> — </span>Motor neuron disease (MND) may precede or follow the development of FTD, which is usually the bvFTD subtype [<a href="#rid41">41,75-81</a>]. In patients with classic amyotrophic lateral sclerosis (ALS) presenting to neuromuscular clinics, 15 to 20 percent have cognitive and behavioral symptoms consistent with bvFTD [<a href="#rid82">82</a>], while up to 50 percent have subtle deficits on neuropsychologic testing [<a href="#rid82">82,83</a>]. The true incidence of subsequent MND in patients who present initially with FTD is less certain. (See  <a class="medical medical_review" href="/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Cognitive symptoms'</a>.)</p><p>The MND associated with bvFTD is generally similar to that seen in classic ALS, with a few exceptions. As in classic ALS, there is involvement of both upper motor neurons (resulting in pyramidal signs such as spasticity and hyperreflexia) and lower motor neurons (resulting in weakness, atrophy, and fasciculations). Bulbar involvement resulting in facial or tongue weakness or dysphagia is more common in patients with FTD-MND than classic ALS. Pseudobulbar affect, or uncontrolled bouts of laughter or crying that are sometimes inconsistent with the patient's actual mood, is commonly seen [<a href="#rid84">84</a>]. </p><p>The behavioral symptoms of FTD-MND are generally similar to those of typical bvFTD. (See <a class="local">'Clinical presentation'</a> above.) </p><p>However, psychotic symptoms are more common in FTD-MND than in bvFTD without MND [<a href="#rid85">85</a>]. This appears to be particularly true in carriers of the <em>C9orf72 </em>repeat expansion, the most commonly identified genetic cause of FTD-MND [<a href="#rid47">47,48,86</a>]. (See  <a class="medical medical_review" href="/d/html/5176.html" rel="external">"Familial amyotrophic lateral sclerosis", section on 'C9ORF72 gene'</a>.)</p><p>There are rare reports of nonfluent variant PPA or semantic variant PPA co-occurring with MND [<a href="#rid87">87,88</a>].</p><p>Neuroimaging in patients with FTD-MND reveals atrophy in premotor regions and precentral gyri, in addition to the frontotemporal atrophy [<a href="#rid31">31</a>]. (See <a class="local">'Neuroimaging'</a> above.)</p><p>Patients with FTD-MND have shorter survival than those with FTD without MND [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H533511936"><span class="h2">Corticobasal syndrome</span><span class="headingEndMark"> — </span>Historically, corticobasal degeneration (CBD) was described as a progressive neurodegenerative disorder characterized by asymmetric parkinsonism, apraxia, myoclonus, dystonia, and alien limb syndrome [<a href="#rid90">90-92</a>]. Over time, clinicopathologic correlation studies have demonstrated that this classical clinical syndrome is poorly predictive of underlying CBD pathology [<a href="#rid93">93</a>], which is a tauopathy characterized by tau-positive neuronal and glial inclusions, achromatic ballooned neurons, and neurodegeneration involving the frontal lobes, basal ganglia, and brainstem [<a href="#rid94">94,95</a>]. </p><p>Other pathologies associated with the clinical corticobasal syndrome (CBS) include Alzheimer pathology, the pathology of progressive supranuclear palsy (PSP; also a tauopathy), FTLD with TDP43-positive inclusions (FTLD-TDP), and Creutzfeldt-Jakob disease. (See  <a class="medical medical_review" href="/d/html/14135.html" rel="external">"Corticobasal degeneration", section on 'Antemortem versus postmortem diagnosis'</a>.)</p><p>Autopsy-proven CBD is a frontal lobe predominant disease [<a href="#rid95">95,96</a>], with motor symptoms sometimes emerging only in advanced stages of disease [<a href="#rid95">95,97-100</a>]. The initial clinical syndrome may take the form of bvFTD, nonfluent variant PPA, executive dysfunction with motor features as identified in the early clinical descriptions of CBS, or PSP [<a href="#rid95">95,97,99,101-105</a>]. </p><p>A lack of early motor findings therefore does not exclude CBD in patients presenting with a clinical syndrome suggestive of FTD. Moreover, CBD manifests with substantial clinical heterogeneity, such that features of bvFTD, nonfluent variant PPA, and CBS may overlap or evolve within patients during their disease course [<a href="#rid98">98,106</a>].</p><p>CBD syndrome is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/14135.html" rel="external">"Corticobasal degeneration"</a>.)</p><p class="headingAnchor" id="H533512332"><span class="h2">Progressive supranuclear palsy</span><span class="headingEndMark"> — </span>PSP is a neurodegenerative syndrome consisting of supranuclear gaze palsy, axial dystonia with a hypererect posture, bradykinesia, rigidity, and falls early in the clinical course [<a href="#rid107">107,108</a>]. </p><p>Most patients with PSP also have changes in cognition and behavior that overlap with bvFTD [<a href="#rid109">109-111</a>]. Apathy and disinhibition are the most common behavioral symptoms and may even precede motor symptoms [<a href="#rid110">110,112,113</a>]. Aggression, hyperorality, and stereotypical motor behavior as seen in patients with bvFTD are not as common in PSP [<a href="#rid114">114</a>].</p><p>PSP is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/14136.html" rel="external">"Progressive supranuclear palsy (PSP): Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H533512474"><span class="h1">GENETIC TESTING</span><span class="headingEndMark"> — </span>In FTD, an autosomal dominant pattern of inheritance is observed in the families of approximately 10 to 25 percent of patients [<a href="#rid53">53,115-119</a>]. An additional 40 percent of patients report a family history of dementia or psychiatric conditions, but without a clear inheritance pattern. </p><p>The most common genetic mutations causing familial FTD include microtubule-associated protein tau (<em>MAPT</em>), progranulin (<em>GRN</em>), and <em>C9orf72 </em>hexanucleotide repeat expansion. Patients with behavioral variant FTD (bvFTD), particularly when associated with motor neuron disease (MND), are most likely to have an inherited condition; in one series, more than half of such patients demonstrated a family history consistent with autosomal dominant inheritance [<a href="#rid119">119</a>]. (See  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'Genetic factors'</a>.)</p><p>The family history, the results of pathologic studies (if available) in the patient or family member, and the clinical syndrome can guide appropriateness for genetic testing [<a href="#rid120">120</a>]. Clinical genetics consultation is encouraged in patients considering genetic testing given the implications of test results to family members and uncertainties about penetrance, particularly in the absence of a family history [<a href="#rid121">121</a>].</p><p>Clinical trials for anti-tau drugs, progranulin-elevating therapies, and compounds that reduce or eliminate the suspected abnormalities derived from the <em>C9orf72</em> repeat expansion are underway. </p><p class="headingAnchor" id="H890617643"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116344.html" rel="external">"Society guideline links: Cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H533512634"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Frontotemporal dementia (FTD) is a common cause of early-onset dementia. Disease onset usually occurs in the sixth decade but can range from the second decade to the ninth.</p><p></p><p class="bulletIndent1">"FTD" is an umbrella term for several clinical presentations: behavioral variant FTD (bvFTD) and two forms of primary progressive aphasia (PPA), nonfluent variant PPA and semantic variant PPA. The underlying pathology of FTD is heterogeneous; each clinical variant is associated with a distinct cluster of neuropathologies. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavioral variant FTD</strong> – BvFTD is the most common clinical subtype and is characterized by progressive personality and behavior changes, including disinhibition, apathy and loss of empathy, hyperorality, and compulsive behaviors. Approximately 15 to 20 percent of patients with bvFTD develop concomitant motor neuron disease (MND). (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Behavioral variant FTD with motor neuron disease'</a> above.)</p><p></p><p class="bulletIndent1">On neuropsychologic tests, patients typically score well in executive function and episodic memory early in the disease course. Impairments in emotion and sarcasm recognition and inability to understand another person's perspective may be evident. Apathy and inattention in patients can make the interpretation of neuropsychologic testing challenging. (See <a class="local">'Neuropsychologic testing'</a> above.)</p><p></p><p class="bulletIndent1">Neuroimaging often reveals unilateral focal frontal and temporal atrophy that may progress to involve both hemispheres as the disease progresses. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1">Diagnostic criteria developed by an international consortium synthesize clinical features, neuroimaging, neuropathology, and genetic testing. (See <a class="local">'Diagnostic criteria for bvFTD'</a> above.)</p><p></p><p class="bulletIndent1">Other disorders in the differential diagnosis should be excluded including primary psychiatric disorders, structural pathology in the frontal or temporal lobes, and other neurodegenerative disorders such as Alzheimer disease (AD) or dementia with Lewy bodies. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary progressive aphasia</strong> – The hallmark of PPA is progressive language disturbance leading to functional impairment with relative preservation of episodic memory and other cognitive domains. Three variants of PPA have been described:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In nonfluent variant PPA, patients present with a motor speech deficit characterized by effortful production of the linguistic units of sound (phonemes). The nonfluent variant is frequently associated with frontotemporal lobar degeneration (FTLD)-tau pathology. (See <a class="local">'Nonfluent variant PPA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In semantic variant PPA, patients have impaired single-word comprehension and object naming and preserved fluency, repetition, and grammar. The semantic variant is frequently associated with FTLD with TDP43-positive inclusions (FTLD-TDP) type C pathology. (See <a class="local">'Semantic variant PPA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The logopenic variant is characterized by impaired word retrieval and sentence repetition, resulting in slow, spontaneous speech with frequent word-finding problems. The logopenic variant is typically associated with Alzheimer pathology. (See <a class="local">'Logopenic variant PPA'</a> above.)</p><p></p><p class="bulletIndent1">Neuroimaging in patients with PPA may demonstrate atrophy in the frontal and/or temporal lobes, in patterns specific to each clinical variant. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1">Diagnostic criteria for PPA require progressive language dysfunction with relative sparing of other cognitive domains. (See <a class="local">'Diagnostic criteria for PPA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Motor syndromes</strong> – Motor syndromes associated with FTD include MND, corticobasal syndrome (CBS), and progressive supranuclear palsy (PSP). (See <a class="local">'Motor syndromes associated with FTD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – Genetic testing is available for several mutations that are known to cause familial FTD syndromes. In the absence of a clinical imperative for diagnosis, however, such testing should be done selectively. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="headingAnchor" id="H498160628"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Bruce L Miller, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pick A. Ueber die Beiehungen der senilen Hirnatrophie zur Aphasie. Prager Medicinische Wochenschrift 1892; 17:165.</a></li><li><a class="nounderline abstract_t">Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. Z Gesamte Neurol Psychiatr 1911; 4:356.</a></li><li><a class="nounderline abstract_t">Johnson JK, Diehl J, Mendez MF, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol 2005; 62:925.</a></li><li><a class="nounderline abstract_t">Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002; 58:1615.</a></li><li><a class="nounderline abstract_t">Rosen HJ, Allison SC, Schauer GF, et al. Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005; 128:2612.</a></li><li><a class="nounderline abstract_t">Rankin KP, Gorno-Tempini ML, Allison SC, et al. Structural anatomy of empathy in neurodegenerative disease. Brain 2006; 129:2945.</a></li><li><a class="nounderline abstract_t">Woolley JD, Gorno-Tempini ML, Seeley WW, et al. Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology 2007; 69:1424.</a></li><li><a class="nounderline abstract_t">Whitwell JL, Sampson EL, Loy CT, et al. VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. Neuroimage 2007; 35:207.</a></li><li><a class="nounderline abstract_t">Piguet O, Petersén A, Yin Ka Lam B, et al. Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol 2011; 69:312.</a></li><li><a class="nounderline abstract_t">Williamson C, Alcantar O, Rothlind J, et al. Standardised measurement of self-awareness deficits in FTD and AD. J Neurol Neurosurg Psychiatry 2010; 81:140.</a></li><li><a class="nounderline abstract_t">Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ 2013; 347:f4827.</a></li><li><a class="nounderline abstract_t">Rankin KP, Salazar A, Gorno-Tempini ML, et al. Detecting sarcasm from paralinguistic cues: anatomic and cognitive correlates in neurodegenerative disease. Neuroimage 2009; 47:2005.</a></li><li><a class="nounderline abstract_t">Shany-Ur T, Poorzand P, Grossman SN, et al. Comprehension of insincere communication in neurodegenerative disease: lies, sarcasm, and theory of mind. Cortex 2012; 48:1329.</a></li><li><a class="nounderline abstract_t">Hornberger M, Piguet O, Graham AJ, et al. How preserved is episodic memory in behavioral variant frontotemporal dementia? Neurology 2010; 74:472.</a></li><li><a class="nounderline abstract_t">Devenney E, Bartley L, Hoon C, et al. Progression in Behavioral Variant Frontotemporal Dementia: A Longitudinal Study. JAMA Neurol 2015; 72:1501.</a></li><li><a class="nounderline abstract_t">Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134:2456.</a></li><li><a class="nounderline abstract_t">Rascovsky K, Hodges JR, Kipps CM, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord 2007; 21:S14.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010; 24:375.</a></li><li><a class="nounderline abstract_t">Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011; 10:162.</a></li><li><a class="nounderline abstract_t">Perry RJ, Graham A, Williams G, et al. Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. Dement Geriatr Cogn Disord 2006; 22:278.</a></li><li><a class="nounderline abstract_t">Knopman DS, Boeve BF, Parisi JE, et al. Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol 2005; 57:480.</a></li><li><a class="nounderline abstract_t">Mendez MF, Shapira JS, McMurtray A, et al. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol 2007; 64:830.</a></li><li><a class="nounderline abstract_t">Pijnenburg YA, Mulder JL, van Swieten JC, et al. Diagnostic accuracy of consensus diagnostic criteria for frontotemporal dementia in a memory clinic population. Dement Geriatr Cogn Disord 2008; 25:157.</a></li><li><a class="nounderline abstract_t">Rosen HJ, Hartikainen KM, Jagust W, et al. Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD. Neurology 2002; 58:1608.</a></li><li><a class="nounderline abstract_t">Broe M, Hodges JR, Schofield E, et al. Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 2003; 60:1005.</a></li><li><a class="nounderline abstract_t">Boccardi M, Sabattoli F, Laakso MP, et al. Frontotemporal dementia as a neural system disease. Neurobiol Aging 2005; 26:37.</a></li><li><a class="nounderline abstract_t">Seeley WW, Crawford R, Rascovsky K, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 2008; 65:249.</a></li><li><a class="nounderline abstract_t">Rosen HJ, Wilson MR, Schauer GF, et al. Neuroanatomical correlates of impaired recognition of emotion in dementia. Neuropsychologia 2006; 44:365.</a></li><li><a class="nounderline abstract_t">Rosso SM, Roks G, Stevens M, et al. Complex compulsive behaviour in the temporal variant of frontotemporal dementia. J Neurol 2001; 248:965.</a></li><li><a class="nounderline abstract_t">Ames D, Cummings JL, Wirshing WC, et al. Repetitive and compulsive behavior in frontal lobe degenerations. J Neuropsychiatry Clin Neurosci 1994; 6:100.</a></li><li><a class="nounderline abstract_t">Whitwell JL, Jack CR Jr, Senjem ML, Josephs KA. Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. Neurology 2006; 66:102.</a></li><li><a class="nounderline abstract_t">Baborie A, Griffiths TD, Jaros E, et al. Pathological correlates of frontotemporal lobar degeneration in the elderly. Acta Neuropathol 2011; 121:365.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77:2034.</a></li><li><a class="nounderline abstract_t">Whitwell JL, Avula R, Senjem ML, et al. Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia. Neurology 2010; 74:1279.</a></li><li><a class="nounderline abstract_t">Bevan-Jones WR, Cope TE, Jones PS, et al. [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry 2018; 89:1032.</a></li><li><a class="nounderline abstract_t">Saint-Aubert L, Lemoine L, Chiotis K, et al. Tau PET imaging: present and future directions. Mol Neurodegener 2017; 12:19.</a></li><li><a class="nounderline abstract_t">Barber R, Snowden JS, Craufurd D. Frontotemporal dementia and Alzheimer's disease: retrospective differentiation using information from informants. J Neurol Neurosurg Psychiatry 1995; 59:61.</a></li><li><a class="nounderline abstract_t">Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994; 57:416.</a></li><li><a class="nounderline abstract_t">Levy ML, Miller BL, Cummings JL, et al. Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol 1996; 53:687.</a></li><li><a class="nounderline abstract_t">Perri R, Koch G, Carlesimo GA, et al. Alzheimer's disease and frontal variant of frontotemporal dementia-- a very brief battery for cognitive and behavioural distinction. J Neurol 2005; 252:1238.</a></li><li><a class="nounderline abstract_t">Kertesz A, Blair M, McMonagle P, Munoz DG. The diagnosis and course of frontotemporal dementia. Alzheimer Dis Assoc Disord 2007; 21:155.</a></li><li><a class="nounderline abstract_t">Bathgate D, Snowden JS, Varma A, et al. Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia. Acta Neurol Scand 2001; 103:367.</a></li><li><a class="nounderline abstract_t">Bozeat S, Gregory CA, Ralph MA, Hodges JR. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2000; 69:178.</a></li><li><a class="nounderline abstract_t">Miller BL, Ikonte C, Ponton M, et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology 1997; 48:937.</a></li><li><a class="nounderline abstract_t">Blennerhassett R, Lillo P, Halliday GM, et al. Distribution of pathology in frontal variant Alzheimer's disease. J Alzheimers Dis 2014; 39:63.</a></li><li><a class="nounderline abstract_t">Mendez MF, Shapira JS, Woods RJ, et al. Psychotic symptoms in frontotemporal dementia: prevalence and review. Dement Geriatr Cogn Disord 2008; 25:206.</a></li><li><a class="nounderline abstract_t">Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012; 135:693.</a></li><li><a class="nounderline abstract_t">Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012; 135:765.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Seeley WW, Kim EJ, et al. Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2007; 22:474.</a></li><li><a class="nounderline abstract_t">Mesulam MM. Primary progressive aphasia. Ann Neurol 2001; 49:425.</a></li><li><a class="nounderline abstract_t">Mesulam MM. Primary progressive aphasia and the language network: the 2013 H. Houston Merritt Lecture. Neurology 2013; 81:456.</a></li><li><a class="nounderline abstract_t">Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76:1006.</a></li><li><a class="nounderline abstract_t">Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006; 59:156.</a></li><li><a class="nounderline abstract_t">Hodges JR. Frontotemporal dementia (Pick's disease): clinical features and assessment. Neurology 2001; 56:S6.</a></li><li><a class="nounderline abstract_t">Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord 2005; 19 Suppl 1:S3.</a></li><li><a class="nounderline abstract_t">Mesulam MM, Grossman M, Hillis A, et al. The core and halo of primary progressive aphasia and semantic dementia. Ann Neurol 2003; 54 Suppl 5:S11.</a></li><li><a class="nounderline abstract_t">Eslinger PJ, Dennis K, Moore P, et al. Metacognitive deficits in frontotemporal dementia. J Neurol Neurosurg Psychiatry 2005; 76:1630.</a></li><li><a class="nounderline abstract_t">Le Rhun E, Richard F, Pasquier F. Natural history of primary progressive aphasia. Neurology 2005; 65:887.</a></li><li><a class="nounderline abstract_t">Josephs KA, Duffy JR, Strand EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129:1385.</a></li><li><a class="nounderline abstract_t">Rosen HJ, Allison SC, Ogar JM, et al. Behavioral features in semantic dementia vs other forms of progressive aphasias. Neurology 2006; 67:1752.</a></li><li><a class="nounderline abstract_t">Neary D, Snowden JS, Mann DM. Familial progressive aphasia: its relationship to other forms of lobar atrophy. J Neurol Neurosurg Psychiatry 1993; 56:1122.</a></li><li><a class="nounderline abstract_t">Snowden JS, Thompson JC, Neary D. Knowledge of famous faces and names in semantic dementia. Brain 2004; 127:860.</a></li><li><a class="nounderline abstract_t">Hodges JR, Patterson K, Ward R, et al. The differentiation of semantic dementia and frontal lobe dementia (temporal and frontal variants of frontotemporal dementia) from early Alzheimer's disease: a comparative neuropsychological study. Neuropsychology 1999; 13:31.</a></li><li><a class="nounderline abstract_t">Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55:335.</a></li><li><a class="nounderline abstract_t">Macoir J, Fossard M, Lefebvre L, et al. Detection Test for Language Impairments in Adults and the Aged-A New Screening Test for Language Impairment Associated With Neurodegenerative Diseases: Validation and Normative Data. Am J Alzheimers Dis Other Demen 2017; 32:382.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64:388.</a></li><li><a class="nounderline abstract_t">Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51:1546.</a></li><li><a class="nounderline abstract_t">Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008; 63:709.</a></li><li><a class="nounderline abstract_t">Josephs KA, Whitwell JL, Duffy JR, et al. Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 2008; 70:25.</a></li><li><a class="nounderline abstract_t">Deramecourt V, Lebert F, Debachy B, et al. Prediction of pathology in primary progressive language and speech disorders. Neurology 2010; 74:42.</a></li><li><a class="nounderline abstract_t">Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurol 2012; 11:545.</a></li><li><a class="nounderline abstract_t">Spinelli EG, Mandelli ML, Miller ZA, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol 2017; 81:430.</a></li><li><a class="nounderline abstract_t">Gefen T, Gasho K, Rademaker A, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain 2012; 135:1554.</a></li><li><a class="nounderline abstract_t">Mesulam MM, Weintraub S, Rogalski EJ, et al. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. Brain 2014; 137:1176.</a></li><li><a class="nounderline abstract_t">Strong MJ. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008; 9:323.</a></li><li><a class="nounderline abstract_t">Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59:1077.</a></li><li><a class="nounderline abstract_t">Josephs KA. Frontotemporal lobar degeneration. Neurol Clin 2007; 25:683.</a></li><li><a class="nounderline abstract_t">Mitsuyama Y. Dementia with motor neuron disease. Neuropathology 2000; 20 Suppl:S79.</a></li><li><a class="nounderline abstract_t">Neary D, Snowden JS, Mann DM. Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). J Neurol Sci 2000; 180:15.</a></li><li><a class="nounderline abstract_t">Ikeda M, Ishikawa T, Tanabe H. Epidemiology of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2004; 17:265.</a></li><li><a class="nounderline abstract_t">Neary D, Snowden JS, Mann DM, et al. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990; 53:23.</a></li><li><a class="nounderline abstract_t">Murphy JM, Henry RG, Langmore S, et al. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol 2007; 64:530.</a></li><li><a class="nounderline abstract_t">Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60:1094.</a></li><li><a class="nounderline abstract_t">Chang JL, Lomen-Hoerth C, Murphy J, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology 2005; 65:75.</a></li><li><a class="nounderline abstract_t">Lillo P, Garcin B, Hornberger M, et al. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol 2010; 67:826.</a></li><li><a class="nounderline abstract_t">Rohrer JD, Isaacs AM, Mizielinska S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 2015; 14:291.</a></li><li><a class="nounderline abstract_t">Caselli RJ, Windebank AJ, Petersen RC, et al. Rapidly progressive aphasic dementia and motor neuron disease. Ann Neurol 1993; 33:200.</a></li><li><a class="nounderline abstract_t">Mitsuyama Y. Presenile dementia with motor neuron disease in Japan: clinico-pathological review of 26 cases. J Neurol Neurosurg Psychiatry 1984; 47:953.</a></li><li><a class="nounderline abstract_t">Olney RK, Murphy J, Forshew D, et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005; 65:1774.</a></li><li><a class="nounderline abstract_t">Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112 ( Pt 5):1171.</a></li><li><a class="nounderline abstract_t">Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40:1203.</a></li><li><a class="nounderline abstract_t">Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18:20.</a></li><li><a class="nounderline abstract_t">Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54 Suppl 5:S15.</a></li><li><a class="nounderline abstract_t">Whitwell JL, Jack CR Jr, Boeve BF, et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010; 75:1879.</a></li><li><a class="nounderline abstract_t">Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70:327.</a></li><li><a class="nounderline abstract_t">Vanvoorst WA, Greenaway MC, Boeve BF, et al. Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy. Parkinsonism Relat Disord 2008; 14:376.</a></li><li><a class="nounderline abstract_t">Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53:1969.</a></li><li><a class="nounderline abstract_t">Kertesz A, McMonagle P, Blair M, et al. The evolution and pathology of frontotemporal dementia. Brain 2005; 128:1996.</a></li><li><a class="nounderline abstract_t">Murray R, Neumann M, Forman MS, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007; 68:1274.</a></li><li><a class="nounderline abstract_t">Geda YE, Boeve BF, Negash S, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2007; 19:77.</a></li><li><a class="nounderline abstract_t">Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003; 18:1224.</a></li><li><a class="nounderline abstract_t">Pillon B, Blin J, Vidailhet M, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995; 45:1477.</a></li><li><a class="nounderline abstract_t">Belfor N, Amici S, Boxer AL, et al. Clinical and neuropsychological features of corticobasal degeneration. Mech Ageing Dev 2006; 127:203.</a></li><li><a class="nounderline abstract_t">Kertesz A, Martinez-Lage P, Davidson W, Munoz DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000; 55:1368.</a></li><li><a class="nounderline abstract_t">Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80:496.</a></li><li><a class="nounderline abstract_t">Kertesz A, Davidson W, McCabe P, et al. Primary progressive aphasia: diagnosis, varieties, evolution. J Int Neuropsychol Soc 2003; 9:710.</a></li><li><a class="nounderline abstract_t">STEELE JC, RICHARDSON JC, OLSZEWSKI J. PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol 1964; 10:333.</a></li><li><a class="nounderline abstract_t">Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996; 55:97.</a></li><li><a class="nounderline abstract_t">Nath U, Ben-Shlomo Y, Thomson RG, et al. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003; 60:910.</a></li><li><a class="nounderline abstract_t">Donker Kaat L, Boon AJ, Kamphorst W, et al. Frontal presentation in progressive supranuclear palsy. Neurology 2007; 69:723.</a></li><li><a class="nounderline abstract_t">Kertesz A, McMonagle P. Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy. J Neurol Sci 2010; 289:138.</a></li><li><a class="nounderline abstract_t">Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47:1.</a></li><li><a class="nounderline abstract_t">Osaki Y, Ben-Shlomo Y, Lees AJ, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 2004; 19:181.</a></li><li><a class="nounderline abstract_t">Bak TH, Caine D, Hearn VC, Hodges JR. Visuospatial functions in atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2006; 77:454.</a></li><li><a class="nounderline abstract_t">Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003; 126:2016.</a></li><li><a class="nounderline abstract_t">Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004; 56:399.</a></li><li><a class="nounderline abstract_t">Hodges JR, Davies R, Xuereb J, et al. Survival in frontotemporal dementia. Neurology 2003; 61:349.</a></li><li><a class="nounderline abstract_t">Le Ber I, Guedj E, Gabelle A, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 2006; 129:3051.</a></li><li><a class="nounderline abstract_t">Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 2005; 65:1817.</a></li><li><a class="nounderline abstract_t">Goldman JS, Rademakers R, Huey ED, et al. An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology 2011; 76:475.</a></li><li><a class="nounderline abstract_t">Turner MR, Al-Chalabi A, Chio A, et al. Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry 2017; 88:1042.</a></li></ol></div><div id="topicVersionRevision">Topic 5070 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ueber die Beiehungen der senilen Hirnatrophie zur Aphasie</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Über eigenartige Krankheitsfälle des späteren Alters</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956163" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Frontotemporal lobar degeneration: demographic characteristics of 353 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12058088" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The prevalence of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16195246" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neuroanatomical correlates of behavioural disorders in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008334" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Structural anatomy of empathy in neurodegenerative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909155" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17240166" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21387376" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Eating and hypothalamus changes in behavioral-variant frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204020" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Standardised measurement of self-awareness deficits in FTD and AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23920254" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical review. Frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501175" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Detecting sarcasm from paralinguistic cues: anatomic and cognitive correlates in neurodegenerative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21978867" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comprehension of insincere communication in neurodegenerative disease: lies, sarcasm, and theory of mind.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142613" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : How preserved is episodic memory in behavioral variant frontotemporal dementia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26501846" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Progression in Behavioral Variant Frontotemporal Dementia: A Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810890" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090417" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20369906" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21147039" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914925" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15786453" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antemortem diagnosis of frontotemporal lobar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562930" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Accuracy of the clinical evaluation for frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18176077" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnostic accuracy of consensus diagnostic criteria for frontotemporal dementia in a memory clinic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12058087" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654969" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Staging disease severity in pathologically confirmed cases of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585344" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Frontotemporal dementia as a neural system disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268196" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16154603" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neuroanatomical correlates of impaired recognition of emotion in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11757960" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Complex compulsive behaviour in the temporal variant of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044031" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Repetitive and compulsive behavior in frontal lobe degenerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401855" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978901" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pathological correlates of frontotemporal lobar degeneration in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22131541" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404309" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28912300" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28219440" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Tau PET imaging: present and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608712" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Frontotemporal dementia and Alzheimer's disease: retrospective differentiation using information from informants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8163988" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8929178" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Alzheimer disease and frontotemporal dementias. Behavioral distinctions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15906058" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Alzheimer's disease and frontal variant of frontotemporal dementia-- a very brief battery for cognitive and behavioural distinction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17545742" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The diagnosis and course of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11421849" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10896690" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9109881" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24121962" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Distribution of pathology in frontal variant Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204254" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Psychotic symptoms in frontotemporal dementia: prevalence and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22300873" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22366793" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166607" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11310619" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897873" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Primary progressive aphasia and the language network: the 2013 H. Houston Merritt Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325651" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Classification of primary progressive aphasia and its variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374817" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical and pathological characterization of progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11402143" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Frontotemporal dementia (Pick's disease): clinical features and assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16317256" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical features of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833362" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The core and halo of primary progressive aphasia and semantic dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291884" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Metacognitive deficits in frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186529" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Natural history of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16613895" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130406" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Behavioral features in semantic dementia vs other forms of progressive aphasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410013" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Familial progressive aphasia: its relationship to other forms of lobar atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14985259" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Knowledge of famous faces and names in semantic dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10067773" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The differentiation of semantic dementia and frontal lobe dementia (temporal and frontal variants of frontotemporal dementia) from early Alzheimer's disease: a comparative neuropsychological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14991811" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cognition and anatomy in three variants of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28639484" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Detection Test for Language Impairments in Adults and the Aged-A New Screening Test for Language Impairment Associated With Neurodegenerative Diseases: Validation and Normative Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18991338" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855500" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412267" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166704" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Progressive aphasia secondary to Alzheimer disease vs FTLD pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940270" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prediction of pathology in primary progressive language and speech disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608668" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The non-fluent/agrammatic variant of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28133816" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Typical and atypical pathology in primary progressive aphasia variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22522938" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24574501" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18752088" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370467" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17659185" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Frontotemporal lobar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11037194" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Dementia with motor neuron disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11090859" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178933" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Epidemiology of frontotemporal lobar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2303828" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Frontal lobe dementia and motor neuron disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420314" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Continuum of frontal lobe impairment in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682312" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Are amyotrophic lateral sclerosis patients cognitively normal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009889" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625088" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638642" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8257465" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rapidly progressive aphasic dementia and motor neuron disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6481390" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Presenile dementia with motor neuron disease in Japan: clinico-pathological review of 26 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344521" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The effects of executive and behavioral dysfunction on the course of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2478251" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Corticobasal degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2381527" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cortical-basal ganglionic degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5634369" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Corticodentatonigral degeneration with neuronal achromasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833363" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098403" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Imaging correlates of pathology in corticobasal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21823158" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Clinicopathological correlations in corticobasal degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17977057" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10599767" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Dementia as the most common presentation of cortical-basal ganglionic degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16033782" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The evolution and pathology of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438218" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Cognitive and motor assessment in autopsy-proven corticobasal degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17308231" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639661" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Corticobasal degeneration as a cognitive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7644044" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310834" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Clinical and neuropsychological features of corticobasal degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087783" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359374" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Criteria for the diagnosis of corticobasal degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12901777" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Primary progressive aphasia: diagnosis, varieties, evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14107684" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558176" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654952" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709703" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Frontal presentation in progressive supranuclear palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19733862" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8710059" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978673" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Accuracy of clinical diagnosis of progressive supranuclear palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543521" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Visuospatial functions in atypical parkinsonian syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12876142" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349867" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Clinicopathological correlates in frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12913196" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Survival in frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071924" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344531" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Comparison of family histories in FTLD subtypes and related tauopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282594" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : An algorithm for genetic testing of frontotemporal lobar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28642287" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Genetic screening in sporadic ALS and FTD.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
